

Rosella Centis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6487515/publications.pdf>

Version: 2024-02-01

218
papers

12,161
citations

22146

59
h-index

31843

101
g-index

224
all docs

224
docs citations

224
times ranked

8545
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberculosis. Lancet, The, 2011, 378, 57-72.	13.7	670
2	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
3	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
5	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. European Respiratory Journal, 2012, 40, 1430-1442.	6.7	346
6	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	6.7	346
7	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	6.7	273
8	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. European Respiratory Journal, 2017, 49, 1700387.	6.7	233
9	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	6.7	226
10	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal, 2013, 42, 252-271.	6.7	211
11	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	6.7	188
12	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	6.7	179
13	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology, 2020, 26, 233-240.	2.1	178
14	Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respiratory Medicine, the, 2015, 3, 220-234.	10.7	172
15	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology, 2021, 27, 151-165.	2.1	172
16	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal, 2009, 34, 387-393.	6.7	170
17	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	6.7	163
18	Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. European Respiratory Journal, 2013, 42, 785-801.	6.7	163

#	ARTICLE	IF	CITATIONS
19	Tuberculosis, social determinants and co-morbidities (including HIV). <i>Pulmonology</i> , 2018, 24, 115-119.	2.1	156
20	Tuberculosis elimination: theory and practice in Europe. <i>European Respiratory Journal</i> , 2014, 43, 1410-1420.	6.7	148
21	Efficacy and safety of meropenem+clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. <i>European Respiratory Journal</i> , 2013, 41, 1386-1392.	6.7	145
22	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	6.7	136
23	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	4.3	133
24	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2008, 31, 1155-1159.	6.7	131
25	Tuberculosis Treatment and Drug Regimens. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a017822-a017822.	6.2	131
26	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
27	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.8	116
28	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. <i>Emerging Infectious Diseases</i> , 2008, 14, 1700-1706.	4.3	113
29	Tuberculosis control in prisons: current situation and research gaps. <i>International Journal of Infectious Diseases</i> , 2015, 32, 111-117.	3.3	113
30	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	6.7	113
31	First tuberculosis cases in Italy resistant to all tested drugs. , 2007, 12, E070517.1.		113
32	Drug-resistant tuberculosis: Past, present, future. <i>Respirology</i> , 2010, 15, 413-432.	2.3	110
33	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2017, 50, 1701462.	6.7	103
34	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 857-871.	4.4	101
35	Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. <i>European Respiratory Journal</i> , 2012, 40, 1081-1090.	6.7	99
36	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. <i>European Respiratory Journal</i> , 2014, 44, 811-815.	6.7	96

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1235-1243.	6.7	92
38	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89
39	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
40	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. <i>European Respiratory Journal</i> , 2016, 48, 935-938.	6.7	84
41	Point of care diagnostics for tuberculosis. <i>Pulmonology</i> , 2018, 24, 73-85.	2.1	84
42	Classifying new anti-tuberculosis drugs: rationale and future perspectives. <i>International Journal of Infectious Diseases</i> , 2017, 56, 181-184.	3.3	82
43	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. <i>European Respiratory Journal</i> , 2019, 53, 1900391.	6.7	81
44	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 797-813.	1.2	78
45	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	7.1	76
46	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 373.	4.1	75
47	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	6.7	75
48	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. <i>European Respiratory Journal</i> , 2012, 39, 619-625.	6.7	74
49	Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. <i>Clinical Infectious Diseases</i> , 2015, 61, S102-S118.	5.8	74
50	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	6.7	71
51	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. <i>European Respiratory Journal</i> , 2016, 47, 1758-1766.	6.7	69
52	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	6.7	67
53	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. <i>Clinical Infectious Diseases</i> , 2012, 54, 1379-1380.	5.8	67
54	Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1503-1507.	6.7	66

#	ARTICLE	IF	CITATIONS
55	New anti-tuberculosis drugs and regimens: 2015 update. <i>ERJ Open Research</i> , 2015, 1, 00010-2015.	2.6	65
56	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 887-895.	5.8	64
57	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	6.7	64
58	Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. <i>European Respiratory Journal</i> , 2017, 49, 1602445.	6.7	63
59	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 1052-1066.	2.3	62
60	Risk factors associated with pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 233-240.	2.6	60
61	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. <i>European Respiratory Journal</i> , 2017, 49, 1700146.	6.7	59
62	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	6.7	59
63	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. <i>Breathe</i> , 2021, 17, 210079.	1.3	59
64	Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. <i>European Respiratory Journal</i> , 2012, 40, 814-822.	6.7	58
65	Recent developments in the diagnosis and management of tuberculosis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16078.	2.6	58
66	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. <i>European Respiratory Journal</i> , 2014, 43, 289-292.	6.7	54
67	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. <i>European Respiratory Journal</i> , 2011, 38, 1221-1223.	6.7	52
68	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. <i>Journal of Thoracic Disease</i> , 2017, 9, 2093-2101.	1.4	52
69	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. <i>European Respiratory Journal</i> , 2019, 53, 1802184.	6.7	51
70	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	6.7	50
71	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2011, 38, 730-733.	6.7	47
72	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. <i>Lancet</i> , The, 2016, 387, 2486-2487.	13.7	47

#	ARTICLE	IF	CITATIONS
73	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 341.	4.1	47
74	Tuberculosis elimination: dream or reality? The case of Cyprus. <i>European Respiratory Journal</i> , 2014, 44, 543-546.	6.7	46
75	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1. <i>European Respiratory Journal</i> , 2013, 42, 288-290.	6.7	45
76	Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. <i>Journal of Thoracic Disease</i> , 2016, 8, E474-E485.	1.4	45
77	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 374-385.	0.7	45
78	COVID-19 and tuberculosis—threats and opportunities. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 757-760.	1.2	45
79	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	4.3	43
80	Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. <i>European Respiratory Journal</i> , 2012, 40, 133-142.	6.7	42
81	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	3.3	41
82	Extensively drug-resistant tuberculosis: back to the future. <i>European Respiratory Journal</i> , 2010, 36, 475-477.	6.7	39
83	Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 305-315.	4.4	39
84	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. <i>Journal of Thoracic Disease</i> , 2016, 8, 2666-2671.	1.4	39
85	Applicability of the shorter Bangladesh regimen™ in high multidrug-resistant tuberculosis settings. <i>International Journal of Infectious Diseases</i> , 2017, 56, 190-193.	3.3	38
86	Drug resistant TB – latest developments in epidemiology, diagnostics and management. <i>International Journal of Infectious Diseases</i> , 2022, 124, S20-S25.	3.3	37
87	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2015, 32, 101-104.	3.3	36
88	Post tuberculosis treatment infectious complications. <i>International Journal of Infectious Diseases</i> , 2020, 92, S41-S45.	3.3	36
89	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. <i>Clinical Infectious Diseases</i> , 2008, 46, 958-959.	5.8	35
90	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 688-694.	2.5	35

#	ARTICLE	IF	CITATIONS
91	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	2.5	34
92	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. European Respiratory Journal, 2016, 47, 1345-1347.	6.7	34
93	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	5.8	34
94	Bacille Calmette-Guerin vaccination: the current situation in Europe. European Respiratory Journal, 2014, 43, 24-35.	6.7	33
95	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. European Respiratory Journal, 2014, 43, 286-289.	6.7	32
96	Compassionate and optimum use of new tuberculosis drugs. Lancet Infectious Diseases, The, 2015, 15, 1131-1132.	9.1	32
97	MDR-TB and XDR-TB: drug resistance and treatment outcomes. European Respiratory Journal, 2009, 34, 778-779.	6.7	30
98	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection, 2019, 78, 35-39.	3.3	30
99	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology, 2021, 27, 403-412.	2.1	30
100	Post-tuberculosis sequelae: the need to look beyond treatment outcome. International Journal of Tuberculosis and Lung Disease, 2020, 24, 761-762.	1.2	29
101	Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 700-705.	1.2	29
102	Clinical standards for the diagnosis, treatment and prevention of TB infection. International Journal of Tuberculosis and Lung Disease, 2022, 26, 190-205.	1.2	29
103	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. European Respiratory Journal, 2016, 48, 1527-1529.	6.7	28
104	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	6.7	27
105	Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences. International Journal of Tuberculosis and Lung Disease, 2017, 21, 727-736.	1.2	27
106	Breaking the barriers: Migrants and tuberculosis. Presse Medicale, 2017, 46, e5-e11.	1.9	26
107	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. Jornal Brasileiro De Pneumologia, 2017, 43, 380-392.	0.7	26
108	Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. European Respiratory Journal, 2016, 48, 946-952.	6.7	25

#	ARTICLE	IF	CITATIONS
109	Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015. <i>European Respiratory Journal</i> , 2017, 49, 1602309.	6.7	25
110	Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. <i>Pulmonology</i> , 2021, 27, 452-455.	2.1	25
111	The need for pulmonary rehabilitation following tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 720-722.	1.2	25
112	On linezolid efficacy and tolerability. <i>European Respiratory Journal</i> , 2012, 39, 770-772.	6.7	23
113	Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. <i>European Respiratory Journal</i> , 2016, 47, 664-667.	6.7	23
114	Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.8	23
115	La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 245-250.	0.8	23
116	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. <i>European Respiratory Journal</i> , 2010, 36, 208-211.	6.7	22
117	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. <i>International Journal of Infectious Diseases</i> , 2017, 56, 30-33.	3.3	22
118	European policies in the management of tuberculosis among migrants. <i>International Journal of Infectious Diseases</i> , 2017, 56, 85-89.	3.3	22
119	TB and COVID-19 co-infection: rationale and aims of a global study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 78-80.	1.2	22
120	Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701414.	6.7	21
121	Multi and extensively drug-resistant pulmonary tuberculosis. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 244-252.	2.6	21
122	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1". <i>European Respiratory Journal</i> , 2012, 40, 497-500.	6.7	20
123	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2017, 49, 1600993.	6.7	20
124	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020, 92, S10-S14.	3.3	20
125	Multidrug-resistant tuberculosis today. <i>Bulletin of the World Health Organization</i> , 2012, 90, 78-78.	3.3	19
126	Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. <i>European Respiratory Journal</i> , 2015, 45, 287-289.	6.7	19

#	ARTICLE	IF	CITATIONS
127	Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. <i>International Journal of Infectious Diseases</i> , 2015, 32, 156-160.	3.3	19
128	Preventing and controlling tuberculosis among refugees in Europe: more is needed. <i>European Respiratory Journal</i> , 2016, 48, 272-274.	6.7	19
129	Migration, TB control and elimination: Whom to screen and treat. <i>Pulmonology</i> , 2018, 24, 99-105.	2.1	19
130	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.6	18
131	Tuberculosis elimination: a dream or a reality? The case of Oman. <i>European Respiratory Journal</i> , 2018, 51, 1702027.	6.7	18
132	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	2.1	18
133	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	3.3	18
134	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. <i>European Respiratory Journal</i> , 2016, 47, 686-688.	6.7	17
135	Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal. <i>European Respiratory Journal</i> , 2015, 45, 292-294.	6.7	16
136	Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Detection: A Systematic Review With Meta-analysis. <i>Frontiers in Medicine</i> , 2022, 9, 870738.	2.6	16
137	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. <i>European Respiratory Journal</i> , 2015, 45, 1170-1173.	6.7	15
138	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	2.6	15
139	Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, 20210044.	0.7	15
140	Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination. <i>European Respiratory Journal</i> , 2015, 45, 289-291.	6.7	14
141	Reversing the tuberculosis upwards trend: a success story in Romania. <i>European Respiratory Journal</i> , 2009, 33, 168-170.	6.7	13
142	Diagnostic performances of the Xpert MTB/RIF in Brazil. <i>Respiratory Medicine</i> , 2018, 134, 12-15.	2.9	13
143	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000. <i>European Respiratory Journal</i> , 2003, 21, 129-134.	6.7	12
144	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0151724.	2.5	12

#	ARTICLE	IF	CITATIONS
145	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1109-1115.	4.4	11
146	Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 337-341.	0.7	11
147	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. <i>Paediatric Drugs</i> , 2016, 18, 13-23.	3.1	11
148	Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 27-30.	0.7	11
149	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	6.7	11
150	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 879-883.	3.0	10
151	Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2012, 367, 2154-2156.	27.0	10
152	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1â€“. <i>European Respiratory Journal</i> , 2012, 39, 1263-1266.	6.7	10
153	Management of drug resistant TB in patients with HIV co-infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2737-2750.	1.8	10
154	Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. <i>European Respiratory Journal</i> , 2018, 51, 1702267.	6.7	10
155	Eliminating tuberculosis in Latin America: making it the point. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 73-76.	0.7	10
156	Multidrug-resistant tuberculosis. <i>Lancet, The</i> , 2019, 394, 298.	13.7	10
157	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
158	Availability of anti-tuberculosis drugs in Europe: Table 1â€“. <i>European Respiratory Journal</i> , 2012, 40, 500-503.	6.7	9
159	Do we need a new Fleming Å©poque: The nightmare of drug-resistant tuberculosis. <i>International Journal of Mycobacteriology</i> , 2013, 2, 123-125.	0.6	9
160	How to manage children who have come into contact with patients affected by tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2015, 1, 1-12.	1.3	9
161	Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe. <i>Travel Medicine and Infectious Disease</i> , 2016, 14, 588-590.	3.0	9
162	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. <i>Journal of Thoracic Disease</i> , 2019, 11, S457-S460.	1.4	9

#	ARTICLE	IF	CITATIONS
163	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. <i>Presse Medicale</i> , 2022, 51, 104112.	1.9	9
164	Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group. <i>Monaldi Archives for Chest Disease</i> , 2000, 55, 293-8.	0.6	9
165	Multidrug- and extensively drug-resistant TB in persons living with HIV. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 245-254.	2.5	8
166	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. <i>European Respiratory Journal</i> , 2015, 45, 571-574.	6.7	8
167	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	2.5	8
168	TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 289-292.	1.2	8
169	The multidrug-resistant tuberculosis threat: old problems and new solutions. <i>Journal of Thoracic Disease</i> , 2015, 7, E354-60.	1.4	8
170	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. <i>Journal of Thoracic Disease</i> , 2015, 7, 1080-5.	1.4	8
171	<i>Mycobacterium tuberculosis</i> Complex Drug Resistance in Italy. <i>Emerging Infectious Diseases</i> , 2004, 10, 752-753.	4.3	7
172	Ripped from the headlines: how can we harness communications to control TB?. <i>European Respiratory Journal</i> , 2007, 30, 194-198.	6.7	7
173	Tuberculosis, one disease, many faces. <i>Monaldi Archives for Chest Disease</i> , 2008, 69, 2-4.	0.6	7
174	Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. <i>Journal of Asthma</i> , 2020, 57, 1365-1371.	1.7	7
175	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210076.	0.7	7
176	Consensus Not Yet Reached on Key Drugs for Extensively Drug-Resistant Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2009, 49, 315-316.	5.8	6
177	Universal health coverage and social support in Senegal: a comprehensive approach against tuberculosis. <i>European Respiratory Journal</i> , 2015, 46, 869-871.	6.7	6
178	Estrategias de la OMS para el tratamiento de la tuberculosis resistente. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.8	6
179	Commemorating World TB Day 2020: "It's TIME" It's time to End the Global TB Epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	3.3	6
180	Post-TB disease: a new topic for investigation and why it matters. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 258-261.	1.2	6

#	ARTICLE	IF	CITATIONS
181	Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20210515.	0.7	6
182	New anti-tuberculosis drugs for special populations: a difficult-to-address issue. <i>European Respiratory Journal</i> , 2016, 48, 957-958.	6.7	5
183	WHO Strategies for the Management of Drug-Resistant Tuberculosis. <i>Archivos De Bronconeumologia</i> , 2017, 53, 95-97.	0.8	5
184	International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180420.	0.7	5
185	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. <i>Antibiotics</i> , 2021, 10, 1355.	3.7	5
186	From the authors:. <i>European Respiratory Journal</i> , 2010, 35, 938-940.	6.7	4
187	Monitoring predictors of mortality: A necessary action to reach TB elimination. <i>Revista Portuguesa De Pneumologia</i> , 2015, 21, 295-298.	0.7	4
188	Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy. <i>European Respiratory Journal</i> , 2015, 46, 274-277.	6.7	4
189	Tuberculosis management and determinants of recurrence. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 3-3.	1.2	4
190	Delamanid: does it have a role in tuberculosis treatment?. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 193-195.	10.7	4
191	The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021, , .	0.8	4
192	Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating. <i>The Lancet Global Health</i> , 2021, 9, e1628-e1629.	6.3	4
193	Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. <i>International Journal of Infectious Diseases</i> , 2017, 65, 133-134.	3.3	3
194	Tuberculosis: an ancient and evergreen disease. <i>European Respiratory Review</i> , 2011, 20, 69-70.	7.1	2
195	TB and MDR-TB: what is new in 2012?. <i>Breathe</i> , 2012, 9, 100-111.	1.3	2
196	Declaration on palliative care for MDR/XDR-TB [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1418-1419.	1.2	2
197	A case of resistance beyond extensively drug-resistant tuberculosis in Japan. <i>European Respiratory Journal</i> , 2013, 42, 872-873.	6.7	2
198	Recommendations for pediatric tuberculosis vaccination in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 644-650.	3.3	2

#	ARTICLE	IF	CITATIONS
199	World TB Day 2017: Strengthening the fight against TB. <i>Presse Medicale</i> , 2017, 46, e1-e4.	1.9	2
200	<i>Epidemiology of TB.</i> , 2012, , 14-25.		2
201	Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals. <i>European Respiratory Journal</i> , 2019, 54, 1901578.	6.7	2
202	WHO recommendations for multidrug-resistant tuberculosis – Authors’ reply. <i>Lancet, The</i> , 2016, 388, 2234-2235.	13.7	1
203	Management of extensively drug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 237-239.	10.7	1
204	Understanding the multidrug-resistant tuberculosis epidemic in China. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 955-955.	1.2	1
205	<i>Tuberculosis, Public Health Aspects.</i> , 2017, , 252-266.		1
206	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702187.	6.7	1
207	TB management in the European Union/European Economic Area: a multi-centre survey. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 126-133.	1.2	1
208	<i>Medical treatment of pulmonary tuberculosis.</i> , 2013, , 11-19.		1
209	Corrigendum. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 447-448.	2.5	0
210	“Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia” Katherine Floyd, Raymond Hutubessy, Kai Kliiman, Rosella Centis, Nina Khurieva, Wieslaw Jakubowiak, Manfred Danilovits, Genadi Peremitin, Salmaan Keshavjee and Giovanni Battista Migliori. <i>Eur Respir J</i> 2012; 40: 133–142. <i>European Respiratory Journal</i> , 2012, 40, 800.1-800.	6.7	0
211	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. <i>European Respiratory Journal</i> , 2015, 46, 1841-1843.	6.7	0
212	<i>Tuberculosis Rehabilitation and Palliative Care.</i> , 2021, , 275-281.		0
213	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , 2016, , .		0
214	Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis. , 2016, , .		0
215	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , .		0
216	Management of tuberculosis in the European Union: a multicentre audit. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
217	Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery. , 2018, , .		0
218	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. Indian Journal of Medical Research, 2017, 145, 261-263.	1.0	0